Article Text

other Versions

PDF
A randomised placebo-controlled interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus
  1. Stephen A Wright (drsawright{at}yahoo.co.uk)
  1. Musgrave Park Hospital, United Kingdom
    1. Fiona M O'Prey (fionaoprey{at}hotmail.com)
    1. Queens University Belfast, United Kingdom
      1. Michelle T McHenry (michellemchenry{at}yahoo.co.uk)
      1. Musgrave Park Hospital, United Kingdom
        1. William J Leahey (w.leahey{at}qub.ac.uk)
        1. Queens University Belfast, United Kingdom
          1. Adrian B Devine (a.devine{at}qub.ac.uk)
          1. Queens University Belfast, United Kingdom
            1. Emeir M Duffy (em.duffy{at}ulster.ac.uk)
            1. University of Ulster, United Kingdom
              1. Dennis G Johnston (g.d.johnston{at}qub.ac.uk)
              1. Queens University Belfast, United Kingdom
                1. Michael B Finch (michael.finch{at}royalhospitals.n-i.nhs.uk)
                1. Musgrave Park Hospital, United Kingdom
                  1. Aubrey L Bell (a.bell{at}qub.ac.uk)
                  1. Musgrave Park Hospital, United Kingdom
                    1. Gary E McVeigh (g.mcveigh{at}qub.ac.uk)
                    1. Queens University Belfast, United Kingdom

                      Abstract

                      Objective: To determine the clinical effect of dietary supplementation with low dose omega-3-polyunsaturated fatty acids on disease activity and endothelial function in patients with systemic lupus erythematosus.

                      Methods: A 24 week randomised double-blind placebo-controlled parallel trial of the effect of 3g of omega-3-polyunsaturated fatty acids on 60 patients with SLE was performed. Serial measurements of disease activity using the revised Systemic Lupus Activity Measure (SLAM-R) and British Isles Lupus Assessment Group index of disease activity for SLE (BILAG), endothelial function using flow mediated dilation of the brachial artery (FMD), oxidative stress using platelet 8-isoprostanes and analysis of platelet membrane fatty acids were taken at baseline, 12 and 24 weeks.

                      Results: In the fish oil group there was a significant improvement at 24 weeks in SLAM-R (from 9.4±3.0 to 6.3±2.5, p<0.001); in BILAG (from 13.6±6.0 to 6.7±3.8, p<0.001); in FMD (from 3.0% (-0.5-8.2) to 8.9% (1.3-16.9), p<0.001) and in platelet 8-isoprostanes (from 177pg/mg protein (23 – 387) to 90 pg/mg protein (32 – 182), p = 0.007).

                      Conclusions: Low dose dietary supplementation with omega-3 fish oils in SLE not only has a therapeutic effect on disease activity but also improves endothelial function and reduces oxidative stress and may therefore confer cardiovascular benefits.

                      • endothelial function
                      • fish oils
                      • SLE

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.